Details for Patent: 8,163,904
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,163,904 protect, and when does it expire?
Patent 8,163,904 protects TASIGNA and is included in one NDA.
Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-three patent family members in thirty-four countries.
Summary for Patent: 8,163,904
| Title: | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
| Abstract: | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]- -3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes. |
| Inventor(s): | Manley; Paul W (Arlesheim, CH), Shieh; Wen-Chung (Berkeley Heights, NJ), Sutton; Paul Allen (Parsippany, NJ), Karpinski; Piotr H (Lincoln Park, NJ), Wu; Raeann (Pine Brook, NJ), Monnier; Stephanie (Raedersheim, FR), Brozio; Jorg (Basel, CH) |
| Assignee: | Novartis AG (Basel, CH) Novartis Pharma GmbH (Vienna, AT) |
| Application Number: | 11/995,898 |
|
Patent Claim Types: see list of patent claims | Compound; Use; Formulation; Composition; |
Drugs Protected by US Patent 8,163,904
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-003 | Mar 22, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-002 | Jun 17, 2010 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-001 | Oct 29, 2007 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,163,904
| PCT Information | |||
| PCT Filed | July 18, 2006 | PCT Application Number: | PCT/US2006/027878 |
| PCT Publication Date: | February 08, 2007 | PCT Publication Number: | WO2007/015871 |
International Family Members for US Patent 8,163,904
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 057467 | See Plans and Pricing | |||
| Austria | 514689 | See Plans and Pricing | |||
| Australia | 2006276205 | See Plans and Pricing | |||
| Australia | 2010241419 | See Plans and Pricing | |||
| Australia | 2012203844 | See Plans and Pricing | |||
| Brazil | PI0613605 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
